[Roxithromycin versus doxycycline in the treatment of Chlamydia trachomatis cervicitis in asymptomatic women].

We have performed an experimental open study, non randomized, in a population of women pertaining to a family planning center, and who have been diagnosed of Chlamydia trachomatis infection through EIA and DNA probe. 75 patients were included in the study, 50 of them received roxitromycine; 150 mg every 12 hours during 10 days, the other 25 being treated with doxycycline, 100 mg each 24 hours during 10 days. All women underwent a control after treatment using both techniques a month later, to asses the efficacy of the treatment. Mean age of women treated with roxitromycine was 28.6 years, and 30 years the ones treated with doxycycline. Efficacy in the eradication of Chlamydia trachomatis was 91.7% in the group treated with macrolide, and 92% in the group treated with doxycycline. Comparison through Chi-square did not yield statistical significance with a p < 0.05. Only a patient treated with doxycycline showed gastric intolerance. Roxitromycine shows an in vivo activity similar to doxycycline, and is an alternative to the use of doxycycline, being the first choice in those women in whom tetracycline are contraindicated.